Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
Prestige BioPharmas trastuzumab (HD201) is a proposed biosimilar to Roches Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer.
- Prestige BioPharmas trastuzumab (HD201) is a proposed biosimilar to Roches Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer.
- Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.
- The license agreement grants Dr. Reddys the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia.
- Lisa S. Park, CEO of Prestige BioPharma, commented: We are delighted to establish a partnership with Dr. Reddys for key Latin American and Southeast Asian markets.